Nearly a quarter of adults worldwide are thought to have non-alcoholic fatty liver disease; between 11% and 40% of them will progress to non-alcoholic steatohepatitis (NASH). Treatments for NASH are urgently required. Liver biopsy, the gold standard for patient identification and stratification, comes with challenges. Beyond being an invasive procedure for patients, recent publications have highlighted variation in inter- and intra-reader pathologist interpretation. These issues highlight the need for non-invasive tools to support drug development.

Join industry leaders for a webinar dedicated to helping you overcome some of the key challenges presented in NASH drug development.

Topics covered will include:

  • Key considerations for liver biopsy collection and interpretation
  • Emerging non-invasive biomarkers and their role in NASH clinical trials
  • The connection between clinical practice and drug development

Featured Speakers

 ‎Robert McGee, MD, PhD

Pathologist and Medical Director
Anatomic Pathology and Histology
Covance by Labcorp, Central Laboratories


Katherine T. Landschulz, PhD

Metabolic Diseases Therapeutic Area Lead
Biomarker Solution Center
Covance by Labcorp


Margery Connelly, PhD, MBA

Strategic Director
Cardiometabolic Disease Diagnostics Research & Development
Labcorp Diagnostics